Login to Your Account



Sunesis Finds New Oncology Partner in $60M Millennium Deal

By Marie Powers


Wednesday, April 6, 2011
Millennium, of Cambridge Mass., has rescued the kinase inhibitor program in oncology at Sunesis Pharmaceuticals Inc. after development partner Biogen Idec exited the oncology market last fall. Millennium, a unit of Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, inked a licensing agreement that covers the development of Sunesis' oral, Phase I-ready selective pan-Raf kinase inhibitor and an additional preclinical kinase inhibitor program with an undisclosed oncology target.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription